Day 2 :
- Multidrug-resistant TB
Location: Radisson Hotel narita, Tokyo, Japan
Session Introduction
Neusa OVT Lopes
Pulmonologist, National Hospital Guido Valadares,Timor Leste
Title: Engaging retail drug outlets or private pharmacy has been translated into programmatic policy, strategy, and intervention in low- and middle-income countries for early detection of TBC cases and prevention of MDR TB
Time : 10.00- 11.00
Biography:
Abstract:
Engaging retail drug outlets has been translated into programmatic policy, strategy, and intervention in low- and middle-income countries. We need to think beyond traditional models that expect pharmacists to be able to recognize who may have TB and passively refer TB patients to the public sector. Pharmacists can be engaged for a variety of TB services across the cascade of care, and private pharmacies have been actively engaged in some development countries that have dramatically increased private sector TB case notifications in the country and improved quality of TB care in the private sector. In addition, a supportive and effective regulatory environment may be as important to help curb the private pharmacy sale of unnecessary antibiotics, and decrease diagnostic delays for millions of TB patients. Successful TB control efforts hinge on early diagnosis and appropriate treatment.
Jean Claude Semuto
Rwanda Biomedical Center, Rwanda
Title: Shortening time to initiate MDR-TB treatment as a strong programmatic control approach: Decline in MDR-TB prevalence, Rwanda history
Time : 11.00-12.00
Biography:
Jean Claude Semuto Ngabonziza is a researcher at the Rwanda Biomedical Center, Kigali, Rwanda, and Ph.D. student at the Institute of Tropical Medicine, Antwerp Belgium. Over 8 years, he has been working at the National Reference Laboratory and Tuberculosis control program, supporting the implementation of different operational research, and new tuberculosis diagnostic tools at the countrywide scale. Currently, his main research area focuses on improving diagnostics for multi-drug tuberculosis.
Abstract:
Statement of the problem: The first cases of multidrug-resistant tuberculosis (MDR-TB) in Rwanda were diagnosed in 1991, while the programmatic management of MDR-TB (including initiation of standardized MDR-TB regimen) started 15 years later (2006). The prevalence of MDR-TB among new TB patients rose from 1.3% in 1993 to 3.9% in 2005. To shorten delays in initiating MDR-TB treatment, subsequent approaches were employed including initiating rapid molecular tools such as MTBDRplus and Xpert MTB/RIF test. Encouragingly, the latest drug resistance survey in 2015 revealed a significant decline in the prevalence of MDR-TB among new tuberculosis patients. We analyzed the delays in initiating MDR-TB treatment and assessed the mortality rate before and after implementing rapid molecular tools.